Naish J, Sturdy P, Toon P
Department of General Practice and Primary Care, Medical College of St Bartholomew's.
BMJ. 1995 Jan 14;310(6972):97-100. doi: 10.1136/bmj.310.6972.97.
To determine the patterns of preventive to reactive prescribing for asthma among general practices in the City and East London Family Health Services Authority area and their relation to prescribing cost.
Descriptive study of asthma prescribing during April 1992 to March 1993. Prescribing data were linked with general practice and population data on one database.
City and East London Family Health Services Authority area, including all general practices in contract with the authority, which covers the inner city London Boroughs of Hackney, Tower Hamlets, and Newham and the Corporation of the City of London.
All 163 general practices as at 1 June 1993.
Ratios of prescribed inhaled corticosteroids plus cromoglycates (prophylactic treatment) to bronchodilators; distribution of the cost of asthma prescribing; distribution of overall generic prescribing; proportion of asthma generic prescribing; distribution of cost of overall drugs prescribed per prescribing unit.
Practices approved for band 3 health promotion or asthma surveillance and those with a general practitioner trainer had on average higher ratios of prophylactic to bronchodilator treatment and significantly higher asthma drug costs than other practices. Those practices with high levels of overall generic prescribing had significantly higher prophylactic to bronchodilator ratios than those with lower levels of generic prescribing. Practices with higher levels of asthma drug generic prescribing also had significantly higher prophylactic prescribing. However, the proportion of generically prescribed asthma drugs was lower than overall generic prescribing. There was no correlation between the ratio of prophylactic to bronchodilator asthma prescribing and the proportion of overall drugs expenditure, but high spending practices spent significantly more on asthma drugs.
Pressure to reduce the cost of asthma prescribing may lead to a lowering of the ratio of prophylactic to bronchodilator treatments. However, reducing prophylactic prescribing would run contrary to the British Thoracic Society guidelines and might worsen the quality of asthma care.
确定伦敦市及东伦敦家庭健康服务管理局辖区内全科医疗中哮喘预防性用药与反应性用药的模式及其与处方成本的关系。
对1992年4月至1993年3月期间哮喘处方的描述性研究。处方数据与一个数据库中的全科医疗及人口数据相关联。
伦敦市及东伦敦家庭健康服务管理局辖区,包括与该管理局签约的所有全科医疗,覆盖伦敦市中心区的哈克尼、陶尔哈姆莱茨和纽汉姆自治市以及伦敦市公司。
截至1993年6月1日的所有163家全科医疗。
吸入性皮质类固醇加色甘酸盐(预防性治疗)与支气管扩张剂的处方比例;哮喘处方成本的分布;总体通用处方的分布;哮喘通用处方的比例;每个处方单位所开全部药物的成本分布。
获得3级健康促进或哮喘监测批准的医疗机构以及有全科医生培训师的医疗机构,预防性治疗与支气管扩张剂治疗的平均比例较高,且哮喘药物成本显著高于其他医疗机构。总体通用处方水平高的医疗机构,其预防性与支气管扩张剂的比例显著高于通用处方水平低的医疗机构。哮喘药物通用处方水平较高的医疗机构预防性处方也显著更高。然而,哮喘药物通用处方的比例低于总体通用处方。哮喘预防性与支气管扩张剂处方比例与总体药物支出比例之间无相关性,但高支出医疗机构在哮喘药物上的花费显著更多。
降低哮喘处方成本的压力可能导致预防性治疗与支气管扩张剂治疗比例降低。然而,减少预防性处方将与英国胸科学会的指南相悖,可能会恶化哮喘护理质量。